Vertex to Participate in Upcoming September Investor Conferences
Vertex to Participate in Upcoming September Investor Conferences
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.BOSTON--(BUSINESS WIRE)--Aug. 22, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
2024年8月22日，福泰製藥公司（納斯達克代碼：VRTX）宣佈參與兩個即將舉行的投資者會議。
- Dr. Reshma Kewalramani, Chief Executive Officer and President, and Charles Wagner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 11:30 a.m. ET.
- Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 9:10 a.m. ET.
- Reshma Kewalramani博士，首席執行官和總裁，以及Charles Wagner，執行副總裁兼首席財務官，將參加摩根士丹利第22屆全球醫療保健年會上的爐邊談話，時間爲2024年9月5日上午11:30。
- Susie Lisa，高級副總裁投資者關係，和Manisha Pai，執行董事投資者關係，將參加Cantor全球醫療保健年會上的爐邊談話，時間爲2024年9月17日上午9:10。
A live webcast of management's remarks will be available through the Vertex website, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.
管理層講話的現場網絡廣播將通過Vertex網站提供，在「投資者」部分的「新聞與事件」頁面下。會議網絡廣播的重播將存檔在公司的網站上。
About Vertex
Vertex是一家全球性的生物技術公司，致力於通過科學創新爲患有嚴重疾病的人創造變革性藥物。該公司已經獲批准的藥物治療多種慢性、縮短壽命的遺傳病的基本原因，包括囊性纖維化、鐮狀細胞病和輸血依賴性β地中海貧血，並在這些疾病中不斷推進臨床和研究計劃。Vertex在其他嚴重疾病領域也有一系列調查治療法的豐富臨床流水線，包括急性和神經性疼痛、APOL1介導的腎臟疾病、常染色體顯性多囊腎病、1型糖尿病、肌強直性營養不良型1和α-1抗胰蛋白酶缺乏症。
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.
Vertex是一家全球生物技術公司，致力於科學創新，爲患有嚴重疾病的人創造變革性藥物。該公司已經批准了治療多種慢性、縮短壽命的遺傳疾病根本原因的藥物，包括囊性纖維化、鐮狀細胞貧血和依賴輸血的β地中海貧血，並且不斷推進這些疾病的臨床和研究項目。Vertex在其他嚴重疾病的廣泛臨床試驗項目中也擁有一個強大的臨床管線，涵蓋多種模式，其對人類生物因果關係有深入的認識，包括急性和神經病性疼痛、APOL1介導的腎病、免疫球蛋白A腎病、常染色體顯性多囊性腎病、1型糖尿病、肌強直型肌營養不良和α-1抗胰蛋白酶缺乏。
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.
Vertex成立於1989年，總部設在波士頓，在倫敦設有國際總部。此外，該公司在北美、歐洲、澳洲、拉丁美洲和中東擁有研發基地和商業辦事處。Vertex一直被認可爲行業內最佳工作場所之一，包括連續14年躋身《科學》雜誌的最佳僱主榜單，並列入《財富》雜誌的100家最佳公司之一。欲了解公司動態和詳細了解Vertex的創新歷史，請訪問 或關注我們的LinkedIn、Facebook、Instagram、YouTube和Twitter/X。
(VRTX-WEB)
(福泰製藥-網頁)
View source version on businesswire.com:
請查看商業線(businesswire.com)的源版本。
Vertex Pharmaceuticals Incorporated
福泰製藥公司
Investors:
InvestorInfo@vrtx.com
投資者：
投資者信息@vrtx.com
Source: Vertex Pharmaceuticals Incorporated
資訊：福泰製藥股份有限公司
譯文內容由第三人軟體翻譯。
